Omega-3 fatty acid status in attention-deficit/hyperactivity disorder

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 4-5, 2006, Pages 299-308

  Antalis, Caryl J ^a   Stevens, Laura J ^a   Campbell, Mary ^b   Pazdro, Robert ^a   Ericson, Karen ^c   Burgess, John R ^a  

^a Department of Foods and Nutrition ^*  (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY PURDUE UNIVERSITY FORT WAYNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; FERRITIN; IRON; MAGNESIUM; OMEGA 3 FATTY ACID; PHOSPHOLIPID; PYRIDOXINE; ZINC;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BIOCHEMISTRY; BLOOD ANALYSIS; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DIETARY INTAKE; ERYTHROCYTE; ETHNOLOGY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING; THIRST; URINALYSIS;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR; CASE-CONTROL STUDIES; DIET; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; FOOD ANALYSIS; FOOD HABITS; HUMANS; MALE; SKIN ABNORMALITIES; THIRST;

EID: 33748965893     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.07.004     Document Type: Article

References (83)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed. (1994), APA, Washington, DC
2. Szatmari P. The epidemiology of attention-deficit hyperactivity disorders. In: Weiss G. (Ed). Child and Adolescent Psychiatry Clinics of North America: Attention deficit disorder (1992), Saunders, Philadelphia 361-372
3. Silver L.B. Attention-deficit/hyperactivity disorder in adult life. Child Adolesc. Psychiatr. Clin. N. Am. 9 (2000) 511-523
4. Barkley R.A. Attenion-Deficit Hyperactivity Disorder: A Handbook of Diagnosis and Treatment (1998), Guilford Press, New York pp. 164-185
5. Castellanos F.X. Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clin. Pediatr. (Philadelphia) 36 (1997) 381-393
6. Taylor E. Developmental neuropsychopathology of attention deficit and impulsiveness. Dev. Psychopathol. 11 (1999) 607-628
7. Faraone S.V., and Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol. Psychiatry 44 (1998) 951-958
8. Jensen P.S. ADHD: current concepts on etiology, pathophysiology, and neurobiology. Child Adolesc. Psychiatr. Clin. N. Am. 9 (2000) 557-572 vii-viii
9. Barkley R.A. Attention-Deficit Hyperactivity Disorder: A Handbook of Diagnosis and Treatment (1998), Guilford Press, New York pp. 164-185
10. Hartsough C.S., and Lambert N.M. Medical factors in hyperactive and normal children: prenatal, developmental, and health history findings. Am. J. Orthopsychiatry 55 (1985) 190-201
11. Stewart M.A., Pitts Jr. F.N., Craig A.G., and Dieruf W. The hyperactive child syndrome. Am. J. Orthopsychiatry 36 (1966) 861-867
12. Leibson C.L., Katusic S.K., Barbaresi W.J., Ransom J., and O'Brien P.C. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. J. Am Med. Assoc. 285 (2001) 60-66
13. Burr G., and Burr M. On the nature and role of the fatty acids essential in nutrition. J. Biol. Chem. 86 (1930) 587-621
14. Hansen A., Haggard M., Boelsche A., Adam D., and Wiese H. Essential fatty acids in infant nutrition. III. Clinical manifestations of linoleic acid deficiency,. J. Nutr. 66 (1958) 565-576
15. Richardson A.J., and Ross M.A. Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum [in process citation]. Prostaglandins Leukot. Essent. Fatty Acids 63 (2000) 1-9
16. Taylor K.E., Higgins C.J., Calvin C.M., Hall J.A., Easton T., McDaid A.M., and Richardson A.J. Dyslexia in adults is associated with clinical signs of fatty acid deficiency [In Process Citation]. Prostaglandins Leukot. Essent. Fatty Acids 63 (2000) 75-78
17. Vancassel S., Durand G., Barthelemy C., Lejeune B., Martineau J., Guilloteau D., Andres C., and Chalon S. Plasma fatty acid levels in autistic children. Prostaglandins Leukot. Essent. Fatty Acids 65 (2001) 1-7
18. Terai K., Munesue T., and Hiratani M. Excessive water drinking behavior in autism. Brain Dev. 21 (1999) 103-106
19. Verghese C., de Leon J., and Josiassen R.C. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Schizophr. Bull. 22 (1996) 455-464
20. de Leon J., Tracy J., McCann E., and McGrory A. Polydipsia and schizophrenia in a psychiatric hospital: a replication study. Schizophr. Res. 57 (2002) 293-301
21. Mercier-Guidez E., and Loas G. Polydipsia and water intoxication in 353 psychiatric inpatients: an epidemiological and psychopathological study. Eur. Psychiatry 15 (2000) 306-311
22. Simopoulos A.P. n-3 fatty acids and human health: defining strategies for public policy. Lipids 36 Suppl (2001) S83-S89
23. Stevens L.J., Zentall S.S., Deck J.L., Abate M.L., Watkins B.A., Lipp S.R., and Burgess J.R. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 62 (1995) 761-768
24. Stevens L., Zentall S., Abate M.L., Kuczek T., and Burgess J. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol. Behav. 59 (1996) 915-920
25. Burgess J.R., Stevens L., Zhang W., and Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 71 (2000) 327S-330S
26. Salem Jr. N., Litman B., Kim H.Y., and Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36 (2001) 945-959
27. Kuperstein F., Yakubov E., Dinerman P., Gil S., Eylam R., Salem Jr. N., and Yavin E. Overexpression of dopamine receptor genes and their products in the postnatal rat brain following maternal n-3 fatty acid dietary deficiency. J. Neurochem. 95 (2005) 1550-1562
28. Moriguchi T., Greiner R.S., and Salem Jr. N. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J. Neurochem. 75 (2000) 2563-2573
29. Moriguchi T., and Salem Jr. N. Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J. Neurochem. 87 (2003) 297-309
30. Connor W.E., and Neuringer M. The effects of n-3 fatty acid deficiency and repletion upon the fatty acid composition and function of the brain and retina. Prog. Clin. Biol. Res. 282 (1988) 275-294
31. Aman M.G., Mitchell E.A., and Turbott S.H. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J. Abnorm. Child Psychol. 15 (1987) 75-90
32. Voigt R.G., Llorente A.M., Jensen C.L., Fraley J.K., Berretta M.C., and Heird W.C. A randomized double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr. 139 (2001) 189-196
33. Richardson A.J., and Puri B.K. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 233-239
34. Stevens L., Zhang W., Peck L., Kuczek T., Grevstad N., Mahon A., Zentall S.S., Arnold L.E., and Burgess J.R. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38 (2003) 1007-1021
35. Hirayama S., Hamazaki T., and Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. Eur. J. Clin. Nutr. 58 (2004) 467-473
36. Hamazaki T., and Hirayama S. The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. Eur. J. Clin. Nutr. 58 (2004) 838
37. Richardson A.J., and Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 115 (2005) 1360-1366
38. Richardson A.J. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids 39 (2004) 1215-1222
39. Heiligenstein E., Conyers L.M., Berns A.R., and Miller M.A. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J. Am. Coll. Health 46 (1998) 185-188
40. Young G.S., Maharaj N.J., and Conquer J.A. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 39 (2004) 117-123
41. Sattler W., Reicher H., Ramos P., Panzenboeck U., Hayn M., Esterbauer H., Malle E., and Kostner G.M. Preparation of fatty acid methyl esters from lipoprotein and macrophage lipid subclasses on thin-layer plates. Lipids 31 (1996) 1302-1310
42. Li Y., and Watkins B.A. Analysis of fatty acids in food lipids. In: Wrolstad R.E. (Ed). Current Protocols in Food Analytical Chemistry (2002), Wiley, New York D1.2.1-D1.2.15
43. Stedman L., Nickel K.P., Castillo S.S., Andrade J., Burgess J.R., and Teegarden D. 1,25-dihydroxyvitamin D inhibits vitamin E succinate-induced apoptosis in C3H10T1/2 cells but not Harvey ras-transfected cells. Nutr. Cancer 45 (2003) 93-100
44. Vatassery G.T., Smith W.E., and Quach H.T. A liquid chromatographic method for the simultaneous determination of alpha-tocopherol and tocopherolquinone in human red blood cells and other biological samples where tocopherol is easily oxidized during sample treatment. Anal. Biochem. 214 (1993) 426-430
45. Lykkesfeldt J., Loft S., and Poulsen H.E. Determination of ascorbic acid and dehydroascorbic acid in plasma by high-performance liquid chromatography with coulometric detection-are they reliable biomarkers of oxidative stress?. Anal. Biochem. 229 (1995) 329-335
46. Moser P.B., and Reynolds R.D. Dietary zinc intake and zinc concentrations of plasma, erythrocytes, and breast milk in antepartum and postpartum lactating and nonlactating women: a longitudinal study. Am. J. Clin. Nutr. 38 (1983) 101-108
47. Ericson K.L., Mahuren J.D., Zubovic Y.M., and Coburn S.P. Use of chlorite to improve HPLC detection of pyridoxal 5′-phosphate. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 823 (2005) 218-220
48. Burgess J.R., and Stevens L.J. Essential fatty acids in relation to attention deficit hyperactivity disorder: an update. In: Peet M., Glen I., and Horrobin D. (Eds). Phospholipid Spectrum Disorder in Psychiatry and Neurology (2003), Marius Press, Carnforth
49. Poppitt S.D., Kilmartin P., Butler P., and Keogh G.F. Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial. Lipids Health Dis. 4 (2005) 30
50. Ross B.M., McKenzie I., Glen I., and Bennett C.P. Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr. Neurosci. 6 (2003) 277-281
51. Mahadik S.P., Evans D., and Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001) 463-493
52. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int. J. Clin. Pharmacol. Ther. 40 (2002) 158-168
53. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., Ozyurt H., and Savas H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 995-1005
54. Roberts L.J., and Morrow J.D. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28 (2000) 505-513
55. Kadiiska M.B., Gladen B.C., Baird D.D., Germolec D., Graham L.B., Parker C.E., Nyska A., Wachsman J.T., Ames B.N., Basu S., Brot N., Fitzgerald G.A., Floyd R.A., George M., Heinecke J.W., Hatch G.E., Hensley K., Lawson J.A., Marnett L.J., Morrow J.D., Murray D.M., Plastaras J., Roberts II L.J., Rokach J., Shigenaga M.K., Sohal R.S., Sun J., Tice R.R., Van Thiel D.H., Wellner D., Walter P.B., Tomer K.B., Mason R.P., and Barrett J.C. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic. Biol. Med. 38 (2005) 698-710
56. Galland L. Impaired essential fatty acid metabolism in latent tetany. Magnesium 4 (1985) 333-338
57. Starobrat-Hermelin B., and Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnes. Res. 10 (1997) 149-156
58. Mousain-Bosc M., Roche M., Rapin J., and Bali J.P. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J. Am. Coll. Nutr. 23 (2004) 545S-548S
59. Zehaluk C.M., and Walker B.L. Effect of pyridoxine on red cell fatty acid composition in mature rats fed an essential fatty acid-deficient diet. J. Nutr. 103 (1973) 1548-1553
60. Guilarte T.R. Vitamin B6 and cognitive development: recent research findings from human and animal studies. Nutr. Rev. 51 (1993) 193-198
61. Tang F.I., and Wei I.L. Vitamin B-6 deficiency prolongs the time course of evoked dopamine release from rat striatum. J. Nutr. 134 (2004) 3350-3354
62. Taysi S. Oxidant/antioxidant status in liver tissue of vitamin B6 deficient rats. Clin. Nutr. 24 (2005) 385-389
63. Schmidt M.E., Kruesi M.J., Elia J., Borcherding B.G., Elin R.J., Hosseini J.M., McFarlin K.E., and Hamburger S. Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys. Psychiatry Res. 54 (1994) 199-210
64. Arnold L.E., and DiSilvestro R.A. Zinc in attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 15 (2005) 619-627
65. Arnold L.E., Bozzolo H., Hollway J., Cook A., DiSilvestro R.A., Bozzolo D.R., Crowl L., Ramadan Y., and Williams C. Serum zinc correlates with parent- and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 15 (2005) 628-636
66. Akhondzadeh S., Mohammadi M.R., and Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 4 (2004) 9
67. Stangl G.I., and Kirchgessner M. Different degrees of moderate iron deficiency modulate lipid metabolism of rats. Lipids 33 (1998) 889-895
68. Konofal E., Lecendreux M., Arnulf I., and Mouren M.C. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 158 (2004) 1113-1115
69. Calder P.C., Yaqoob P., Thies F., Wallace F.A., and Miles E.A. Fatty acids and lymphocyte functions. Br. J. Nutr. 87 Suppl 1 (2002) S31-S48
70. Dantzer R. Innate immunity at the forefront of psychoneuroimmunology. Brain Behav. Immun. 18 (2004) 1-6
71. Merrill J.E., and Jonakait G.M. Interactions of the nervous and immune systems in development, normal brain homeostasis, and disease. Faseb J. 9 (1995) 611-618
72. Wank R. Schizophrenia and other mental disorders require long-term adoptive immunotherapy. Med. Hypotheses 59 (2002) 154-158
73. Mittleman B.B., Castellanos F.X., Jacobsen L.K., Rapoport J.L., Swedo S.E., and Shearer G.M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol. 159 (1997) 2994-2999
74. Segman R.H., Meltzer A., Gross-Tsur V., Kosov A., Frisch A., Inbar E., Darvasi A., Levy S., Goltser T., Weizman A., and Galili-Weisstub E. Preferential transmission of interleukin-1 receptor antagonist alleles in attention deficit hyperactivity disorder. Mol. Psychiatry 7 (2002) 72-74
75. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 (2005) 237-248
76. Ghosh M.C., Mondal A.C., Basu S., Banerjee S., Majumder J., Bhattacharya D., and Dasgupta P.S. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol. 3 (2003) 1019-1026
77. Chi D.S., Qui M., Krishnaswamy G., Li C., and Stone W. Regulation of nitric oxide production from macrophages by lipopolysaccharide and catecholamines. Nitric Oxide 8 (2003) 127-132
78. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., and Moots R.J. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132 (2002) 34-40
79. Mignini F., Streccioni V., and Amenta F. Autonomic innervation of immune organs and neuroimmune modulation. Autonom. Autacoid Pharmacol. 23 (2003) 1-25
80. Delrue-Perollet C., Li K.S., Vitiello S., and Neveu P.J. Peripheral catecholamines are involved in the neuroendocrine and immune effects of LPS. Brain Behav. Immun. 9 (1995) 149-162
81. Zimmer L., Delion-Vancassel S., Durand G., Guilloteau D., Bodard S., Besnard J., and Chalon S. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J. Lipid Res. 41 (2000) 32-40
82. Levant B., Radel J.D., and Carlson S.E. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Behav. Brain Res. 152 (2004) 49-57
83. Folch J., Lees M., and Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509